EX-15.2 14 ex152eyconsentletter2017.htm EXHIBIT 15.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent the use of our report dated March 8, 2018 with respect to the consolidated financial statements of Oncolytics Biotech Inc. (Oncolytics) as at December 31, 2017 and 2016 and for each of the years in the three year period ended December 31, 2017, included in the Annual Report on Form 20-F of Oncolytics for the year ended December 31, 2017, as filed with the United States Securities Exchange Commission (SEC).
We also consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333- 171625 and 333-205708) of our report dated March 8, 2018 with respect to the consolidated financial statements of Oncolytics as at December 31, 2017 and 2016 and for each of the years in the three year period ended December 31, 2017, included in the Annual Report on Form 20-F of Oncolytics for the year ended December 31, 2017, as filed with the SEC.

Calgary, Canada |  |
March 19, 2018 |